AMP-36 exhibits potent therapeutic efficacy against MRSA pneumonia through membrane-target mechanism

1. Chastre, J. & Fagon, J. Y. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165, 867–903. https://doi.org/10.1164/ajrccm.165.7.2105078 (2002).

   Google Scholar 

2. Sopena, N. & Sabrià, M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 127, 213–219. https://doi.org/10.1378/chest.127.1.213 (2005).

   Google Scholar 

3. Alara, J. A. & Alara, O. R. An overview of the global alarming increase of multiple drug resistant: A major challenge in clinical diagnosis. Infect. Disord. Drug. Target. 24, e250723219043. https://doi.org/10.2174/1871526523666230725103902 (2024).

   Google Scholar 

4. Chambers, H. F. & Deleo, F. R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629–641. https://doi.org/10.1038/nrmicro2200 (2009).

   Google Scholar 

5. Grousd, J. A., Rich, H. E. & Alcorn, J. F. Host-pathogen interactions in Gram-positive bacterial pneumonia. Clin. Microbiol. Rev. https://doi.org/10.1128/cmr.00107-18 (2019).

   Google Scholar 

6. Gardete, S. & Tomasz, A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 124, 2836–2840. https://doi.org/10.1172/jci68834 (2014).

   Google Scholar 

7. Mahlapuu, M., Håkansson, J., Ringstad, L. & Björn, C. Antimicrobial peptides: An emerging category of therapeutic agents. Front. Cell. Infect. Microbiol. 6, 194. https://doi.org/10.3389/fcimb.2016.00194 (2016).

   Google Scholar 

8. Izadpanah, A. & Gallo, R. L. Antimicrobial peptides. J. Am. Acad. Dermatol. 52(3), 381–390. https://doi.org/10.1016/j.jaad.2004.08.026 (2005).

   Google Scholar 

9. Chen, P. et al. Aggregation-prone antimicrobial peptides target gram-negative bacterial nucleic acids and protein synthesis. Acta Biomater. 192, 446–460. https://doi.org/10.1016/j.actbio.2024.12.002 (2025).

   Google Scholar 

10. Sneideris, T. et al. Targeting nucleic acid phase transitions as a mechanism of action for antimicrobial peptides. Nat. Commun. 14, 7170. https://doi.org/10.1038/s41467-023-42374-4 (2023).

    Google Scholar 

11. Pedron, C. N. et al. Molecular hybridization strategy for tuning bioactive peptide function. Commun. Biol. 6, 1067. https://doi.org/10.1038/s42003-023-05254-7 (2023).

    Google Scholar 

12. Mwangi, J., Kamau, P. M., Thuku, R. C. & Lai, R. Design methods for antimicrobial peptides with improved performance. Zool. Res. 44, 1095–1114. https://doi.org/10.24272/j.issn.2095-8137.2023.246 (2023).

    Google Scholar 

13. Wang, G. et al. Design of antimicrobial peptides: progress made with human cathelicidin LL-37. Adv. Exp. Med. Biol. 1117, 215–240. https://doi.org/10.1007/978-981-13-3588-4_12 (2019).

    Google Scholar 

14. Moulick, S., Bera, R. & Roy, D. N. Bactericidal action of ginger (Zingiber officinale Roscoe) extract against Escherichia coli through synergistic modulation of the AcrAB-TolC efflux pump and inhibition of peptidoglycan synthesis: In vitro and in silico approaches. Microb. Pathog. 204, 107624. https://doi.org/10.1016/j.micpath.2025.107624 (2025).

    Google Scholar 

15. de Breij, A. et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aan4044 (2018).

    Google Scholar 

16. van Gent, M. E. et al. Encapsulation of SAAP-148 in octenyl succinic anhydride-modified hyaluronic acid nanogels for treatment of skin wound infections. Pharmaceutics https://doi.org/10.3390/pharmaceutics15020429 (2023).

    Google Scholar 

17. Tolos Vasii, A. M. et al. Anticancer potential of antimicrobial peptides: Focus on buforins. Polymers https://doi.org/10.3390/polym16060728 (2024).

    Google Scholar 

18. Park, C. B., Kim, H. S. & Kim, S. C. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244, 253–257. https://doi.org/10.1006/bbrc.1998.8159 (1998).

    Google Scholar 

19. Kong, D. et al. Mesenchymal stem cells significantly improved treatment effects of Linezolid on severe pneumonia in a rabbit model. Biosci. Rep. https://doi.org/10.1042/bsr20182455 (2019).

20. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucl. Acid. Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).

    Google Scholar 

21. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951. https://doi.org/10.1002/pro.3715 (2019).

    Google Scholar 

22. Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucl. Acid. Res. 53, D672-d677. https://doi.org/10.1093/nar/gkae909 (2025).

    Google Scholar 

23. Russell, L., Pène, F. & Martin-Loeches, I. Multidrug-resistant bacteria in the grey shades of immunosuppression. Intensiv. Care Med. 49, 216–218. https://doi.org/10.1007/s00134-022-06968-8 (2023).

    Google Scholar 

24. Ruhnke, M., Arnold, R. & Gastmeier, P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 15, e606–e619. https://doi.org/10.1016/s1470-2045(14)70344-4 (2014).

    Google Scholar 

25. Costa, B., Martínez-de-Tejada, G., Gomes, P. A. C., Mc, L. M. & Costa, F. Antimicrobial peptides in the battle against orthopedic implant-related infections: A review. Pharmaceutics https://doi.org/10.3390/pharmaceutics13111918 (2021).

    Google Scholar 

26. Chen, C. H., Bepler, T., Pepper, K., Fu, D. & Lu, T. K. Synthetic molecular evolution of antimicrobial peptides. Curr. Opin. Biotechnol. 75, 102718. https://doi.org/10.1016/j.copbio.2022.102718 (2022).

    Google Scholar 

27. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2 (2021).

    Google Scholar 

28. Koehbach, J. & Craik, D. J. The vast structural diversity of antimicrobial peptides. Trend. Pharmacol. Sci. 40, 517–528. https://doi.org/10.1016/j.tips.2019.04.012 (2019).

    Google Scholar 

29. Pirtskhalava, M. et al. DBAASP v3: Database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics. Nucl. Acid. Res. 49, D288-d297. https://doi.org/10.1093/nar/gkaa991 (2021).

    Google Scholar 

30. Wang, G., Li, X. & Wang, Z. APD3: The antimicrobial peptide database as a tool for research and education. Nucl. Acid. Res. 44, D1087-1093. https://doi.org/10.1093/nar/gkv1278 (2016).

    Google Scholar 

31. Hu, H. et al. Hybrid biomimetic membrane coated particles-mediated bacterial ferroptosis for acute MRSA pneumonia. ACS Nano 17, 11692–11712. https://doi.org/10.1021/acsnano.3c02365 (2023).

    Google Scholar 

32. Cruz-Adalia, A. & Veiga, E. Close encounters of lymphoid cells and bacteria. Front. Immunol. 7, 405. https://doi.org/10.3389/fimmu.2016.00405 (2016).

    Google Scholar 

33. Fang, Y. et al. Transcriptomic and metabolomic investigation of molecular inactivation mechanisms in Escherichia coli triggered by graphene quantum dots. Chemosphere 311, 137051. https://doi.org/10.1016/j.chemosphere.2022.137051 (2023).

    Google Scholar 

34. Lin, S., Wang, Y., Lu, Q., Zhang, B. & Wu, X. Combined transcriptome and metabolome analyses reveal the potential mechanism for the inhibition of Penicillium digitatum by X33 antimicrobial oligopeptide. Bioresour. Bioprocess. 8, 120. https://doi.org/10.1186/s40643-021-00472-5 (2021).

    Google Scholar 

35. Camici, M., Allegrini, S. & Tozzi, M. G. Interplay between adenylate metabolizing enzymes and AMP-activated protein kinase. FEBS J. 285, 3337–3352. https://doi.org/10.1111/febs.14508 (2018).

    Google Scholar 

36. Mehra, R. K. & Drabble, W. T. Dual control of the gua operon of Escherichia coli K12 by adenine and guanine nucleotides. Microbiology 123, 27–37. https://doi.org/10.1099/00221287-123-1-27 (1981).

    Google Scholar 

37. Kong, C., Neoh, H. M. & Nathan, S. Targeting Staphylococcus aureus toxins: A potential form of anti-virulence therapy. Toxins https://doi.org/10.3390/toxins8030072 (2016).

    Google Scholar 

38. Recsei, P. et al. Regulation of exoprotein gene expression in Staphylococcus aureus by agar. Mol. Gen. Genet. 202, 58–61. https://doi.org/10.1007/bf00330517 (1986).

    Google Scholar 

39. Capra, E. J. & Laub, M. T. Evolution of two-component signal transduction systems. Annu. Rev. Microbiol. 66, 325–347. https://doi.org/10.1146/annurev-micro-092611-150039 (2012).

    Google Scholar 

40. Bai, J. et al. The role of ArlRS in regulating oxacillin susceptibility in methicillin-resistant Staphylococcus aureus indicates it is a potential target for antimicrobial resistance breakers. Emerg. Microbes. Infect. 8, 503–515. https://doi.org/10.1080/22221751.2019.1595984 (2019).

    Google Scholar 

41. Zhao, N. et al. Molybdopterin biosynthesis pathway contributes to the regulation of SaeRS two-component system by ClpP in Staphylococcus aureus. Virulence 13, 727–739. https://doi.org/10.1080/21505594.2022.2065961 (2022).

    Google Scholar 

42. Lycklama, A. N. J. A. & Driessen, A. J. The bacterial Sec-translocase: Structure and mechanism. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 1016–1028. https://doi.org/10.1098/rstb.2011.0201 (2012).

    Google Scholar 

43. Feltcher, M. E. & Braunstein, M. Emerging themes in SecA2-mediated protein export. Nat. Rev. Microbiol. 10, 779–789. https://doi.org/10.1038/nrmicro2874 (2012).

    Google Scholar 

Download references

Authors and Affiliations

1. Department of Hematology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China

   Yanxiao Han, Lin Cheng, Chenxi Sun, Jialin Song, Yang Jiang, Xiaoyan Li, Dexiao Kong & Chengyun Zheng

2. Institute of Biotherapy for Hematological Malignancy, Shandong University, Jinan, Shandong, China

   Yanxiao Han, Lin Cheng, Chenxi Sun, Jialin Song, Yang Jiang, Xiaoyan Li, Dexiao Kong & Chengyun Zheng

3. Shandong University-Karolinska Institute Collaboration Laboratory for Stem Cell Research, Jinan, Shandong, China

   Yanxiao Han, Lin Cheng, Chenxi Sun, Jialin Song, Yang Jiang, Xiaoyan Li, Dexiao Kong & Chengyun Zheng

4. Department of Clinical Laboratory, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China

   Yuli Wang

5. Emergency Department, Shengli Oilfield Central Hospital, Dongying, Shandong, China

   Xunqi Zhang

6. Shenzhen Weigao Shengji Medical Technology Co., Ltd, Shenzhen, China

   Xuhua Zhang

Contributions

YXH: Methodology, Data curation, Formal analysis, Validation, Visualization, Writing–original draft. YLW: Investigation, Resources. LC: Methodology, Software. CXS: Software. JLS: Software. XQZ: Methodology. XHZ: Methodology. YJ: Data curation, Resources. XYL: Supervision. DXK: Supervision, revising manuscript. CYZ: Conceptualization, Project administration, Supervision, Funding acquisition, Writing-review & editing. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Xiaoyan Li, Dexiao Kong or Chengyun Zheng.

Competing interests

For the invention patent of the AMP-36 in this article (Patent No.: ZL 2024 1 1479080.3, Status: Granted), the corresponding author Chengyun Zheng is the first inventor and the first author Yanxiao Han is the second inventor. The patent rights belong to the Second Hospital of Shandong University. The patent has not been licensed, and no economic benefits have been obtained by the authors or their institutions from it.

Ethical approval

Animal experiments were approved by the Ethics Committee of the Second Hospital of Shandong University with the approval number: No. KYLL-2024SCR001.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions